Edesa Biotech reports Q3 net loss of $1.7M; advances EB06 manufacturing for vitiligo Phase 2

Edesa Biotech, Inc.

Net loss of $1.7M ($0.25/sh) for quarter ended June 30, 2025, unchanged from $1.7M ($0.52/sh) YoY.
Operating expenses flat at $1.9M; R&D $0.9M, G&A $1.0M.
Cash and cash equivalents $12.4M, working capital $12.1M at June 30, 2025.
EB06 Phase 2 vitiligo IND data submission to FDA planned by end of calendar 2025; manufacturing activities ongoing.
EB05 program benefits from fully funded U.S. government platform study; first randomizations completed.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.